Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mikkel Ostergaard

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Annals of the Rheumatic Diseases|April 26, 2012
Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registryLykke Midtbøll Ornbjerg, Mikkel Ostergaard, Pernille Bøyesen, et al.
The Journal of Rheumatology|March 9, 2007
Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schemaMarissa N Lassere, Kent R Johnson, Maarten Boers, et al.
Annals of the Rheumatic Diseases|September 11, 2009
Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitorsSusanne Juhl Pedersen, Inge Juul Sørensen, Kay-Geert A Hermann, et al.
RMD Open|January 6, 2021
Self-protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: results and predictors in more than 12 000 patients with inflammatory rheumatic diseases followed in the Danish DANBIO registryBente Glintborg, Dorte Vendelbo Jensen, Sara Engel, et al.
The Journal of Rheumatology|September 3, 2011
Update on research and future directions of the OMERACT MRI inflammatory arthritis groupPhilip G Conaghan, Fiona M McQueen, Paul Bird, et al.
The Journal of Rheumatology|August 13, 2009
Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkersSilje W Syversen, Robert Landewe, Désirée van der Heijde, et al.
The Journal of Rheumatology|May 4, 2010
Uncoupling of collagen II metabolism in newly diagnosed, untreated rheumatoid arthritis is linked to inflammation and antibodies against cyclic citrullinated peptidesAnne Friesgaard Christensen, Kim Hørslev-Petersen, Stephan Christgau, et al.
The Journal of Rheumatology|August 13, 2009
Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteriaWalter P Maksymowych, Robert Landewé, Paul-Peter Tak, et al.
The Journal of Rheumatology|December 7, 2005
Musculoskeletal ultrasound including definitions for ultrasonographic pathologyRichard J Wakefield, Peter V Balint, Marcin Szkudlarek, et al.
The Journal of Rheumatology|April 3, 2014
Updating the OMERACT filter: discrimination and feasibilityGeorge Wells, Dorcas E Beaton, Peter Tugwell, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Annals of the Rheumatic Diseases|April 26, 2012
Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registryLykke Midtbøll Ornbjerg, Mikkel Ostergaard, Pernille Bøyesen, et al.
The Journal of Rheumatology|March 9, 2007
Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schemaMarissa N Lassere, Kent R Johnson, Maarten Boers, et al.
Annals of the Rheumatic Diseases|September 11, 2009
Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitorsSusanne Juhl Pedersen, Inge Juul Sørensen, Kay-Geert A Hermann, et al.
RMD Open|January 6, 2021
Self-protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: results and predictors in more than 12 000 patients with inflammatory rheumatic diseases followed in the Danish DANBIO registryBente Glintborg, Dorte Vendelbo Jensen, Sara Engel, et al.
The Journal of Rheumatology|September 3, 2011
Update on research and future directions of the OMERACT MRI inflammatory arthritis groupPhilip G Conaghan, Fiona M McQueen, Paul Bird, et al.
The Journal of Rheumatology|August 13, 2009
Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkersSilje W Syversen, Robert Landewe, Désirée van der Heijde, et al.
The Journal of Rheumatology|May 4, 2010
Uncoupling of collagen II metabolism in newly diagnosed, untreated rheumatoid arthritis is linked to inflammation and antibodies against cyclic citrullinated peptidesAnne Friesgaard Christensen, Kim Hørslev-Petersen, Stephan Christgau, et al.
The Journal of Rheumatology|August 13, 2009
Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteriaWalter P Maksymowych, Robert Landewé, Paul-Peter Tak, et al.
The Journal of Rheumatology|December 7, 2005
Musculoskeletal ultrasound including definitions for ultrasonographic pathologyRichard J Wakefield, Peter V Balint, Marcin Szkudlarek, et al.
The Journal of Rheumatology|April 3, 2014
Updating the OMERACT filter: discrimination and feasibilityGeorge Wells, Dorcas E Beaton, Peter Tugwell, et al.
Pageof 10